Liu Shiyue, Wang Yu, Zhu Xingwang, Chen Feifan, Shi Yuan
Department of Neonatology, Children's Hospital of Chongqing Medical University, Chongqing, 400,014, China.
National Clinical Research Center for Child Health and Disorders, Hangzhou, 400,014, China.
BMC Pulm Med. 2024 Dec 30;24(1):637. doi: 10.1186/s12890-024-03429-4.
To compare five pulmonary surfactant (PS) administration strategies for neonates with respiratory distress syndrome (RDS), including intubation-surfactant-extubation (InSurE), thin catheter administration, laryngeal mask airway (LMA), surfactant nebulization (SN), and usual care, with a particular emphasis on the comparison of the LMA and SN with other strategies.
We conducted a systematic search of MEDLINE, EMBASE, PUBMED, and Cochrane CENTRAL databases up to November 2023. Two authors independently conducted data extraction, and assessed bias using the Cochrane Risk of Bias Tool. Frequency-based random-effects network meta-analyses were executed.
A total of 36 trials and 4035 infants were included in the analysis. LMA (OR: 0.20, 95%CI: 0.09 to 0.42) and Less Invasive Surfactant Administration (LISA) (OR: 0.17, 95%CI: 0.09 to 0.32) significantly reduced intubation rates compared to usual care. SN had a higher intubation rate compared to LISA (OR: 3.36, 95%CI: 1.46 to 7.71) and LMA (OR: 2.92, 95%CI: 1.10 to 7.71). LMA had a higher incidence of BPD compared to LISA (OR: 2.59, 95%CI: 1.21 to 5.54). SN ranked second to LISA in preventing BPD and death, but its efficacy decreased after excluding high-risk studies. SN and LMA had the lowest incidence of adverse events during administration.SN had the highest likelihood of secondary administration. Most results were rated as low or very low quality, with findings related to SN significantly impacted by high-risk trials.
The thin catheter strategy minimized intubation risk and showed a better composite effect in reducing both mortality and BPD incidence. SN and LMA each showed safety and some clinical benefits in the subpopulations where they were studied, but their efficacy needs further validation through high-quality studies.
This study was registered in PROSPERO (CRD42023463756).
比较五种用于新生儿呼吸窘迫综合征(RDS)的肺表面活性物质(PS)给药策略,包括插管-表面活性物质-拔管(InSurE)、细导管给药、喉罩气道(LMA)、表面活性物质雾化(SN)和常规护理,特别强调LMA和SN与其他策略的比较。
我们对截至2023年11月的MEDLINE、EMBASE、PUBMED和Cochrane CENTRAL数据库进行了系统检索。两位作者独立进行数据提取,并使用Cochrane偏倚风险工具评估偏倚。进行了基于频率的随机效应网络荟萃分析。
分析共纳入36项试验和4035名婴儿。与常规护理相比,LMA(比值比:0.20,95%置信区间:0.09至0.42)和微创表面活性物质给药(LISA)(比值比:0.17,95%置信区间:0.09至0.32)显著降低了插管率。与LISA(比值比:3.36,95%置信区间:1.46至7.71)和LMA(比值比:2.92,95%置信区间:1.10至7.71)相比,SN的插管率更高。与LISA相比,LMA的支气管肺发育不良(BPD)发生率更高(比值比:2.59,95%置信区间:1.21至5.54)。在预防BPD和死亡方面,SN仅次于LISA,但排除高危研究后其疗效降低。SN和LMA在给药期间不良事件发生率最低。SN二次给药的可能性最高。大多数结果被评为低质量或极低质量,与SN相关的结果受高危试验影响显著。
细导管策略将插管风险降至最低,在降低死亡率和BPD发生率方面显示出更好的综合效果。SN和LMA在各自研究的亚组中均显示出安全性和一些临床益处,但它们的疗效需要通过高质量研究进一步验证。
本研究已在PROSPERO注册(CRD42023463756)。